Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV).

Enocitabine is an anti-tumor agent and an antineoplastic. A derivative of Cytarabine.

Enalapril maleate (Vasotec)

Enadoline (CI 977.

EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.

EML-405 (EML405) is a small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 14 uM.

Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro.

EMD534085 is a kinesin inhibitor currently in clinical development.

EMD-281014 is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels.

EMD-281014 hydrochloride is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels.

Emamectin Benzoate works as a chloride channel activator by binding gamma aminobutyric acid (GABA) receptor and glutamate-gated chloride channels disrupting nerve signals within arthropods.

EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain..

Elubrixin (SB-656933, GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Elocalcitol

ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease.

Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events.

Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist.

Elaiophylin (Gopalamicin.

Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity.

eIF4A3 inhibitor 53a is a potent, selective and cell-active eukaryotic initiation factor 4A3 (eIF4A3) inhibitor with IC50 of 0.26 uM, SPR Kd of 43 nM.

EHT 5372 is a novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

Eggmanone is a potent, selective inhibitor of PDE4 with (IC50=72 nM) that antagonizes the Hedgehog signaling pathway.

EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.

Eg5 Inhibitor V, trans-24 is a potent and specific Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer.

EG01377 is a potent and bioavailable inhibitor of the NRP1/VEGF-A interaction (Kd=1.32 uM), selective for NRP1 over the closely related protein NRP2.

EG00229 is a specific inhibitor of neuropilin-1 (NRP1)/VEGF-A interaction, inhibits the binding of biotinylated VEGFA to NRP1 with IC50 of 8 uM.

eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.

Eflornithine(Difluoromethylornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours.

Efipladib (PLA 902) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 20 nM for LTB4 inhibition.